Tabrecta (capmatinib) vs Krazati (adagrasib)

Tabrecta (capmatinib) and Krazati (adagrasib) are both oral medications used to treat non-small cell lung cancer (NSCLC) with specific genetic mutations known as MET exon 14 skipping mutations. Tabrecta is a MET inhibitor that was the first targeted therapy approved for adult patients with metastatic NSCLC harboring these mutations. Krazati, on the other hand, is a newer KRAS G12C inhibitor that targets a different mutation, the KRAS G12C mutation, which is distinct from the MET exon 14 skipping mutation and is used in treating NSCLC patients with this specific genetic alteration. For a patient deciding between these two medications, it is crucial to have their tumor tested for genetic mutations, as the effectiveness of each drug is contingent upon the presence of the specific mutation it targets. Therefore, the choice between Tabrecta and Krazati would be determined by the patient's individual tumor genetics, and a healthcare provider would recommend the appropriate medication based on the results of the genetic testing.

Difference between Tabrecta and Krazati

Metric	Tabrecta (capmatinib)	Krazati (adagrasib)
Generic name	Capmatinib	Adagrasib
Indications	Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations	Adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy
Mechanism of action	Capmatinib is a kinase inhibitor that targets MET, including MET exon 14 skipping mutations	Adagrasib is a small molecule that irreversibly and selectively binds to KRAS G12C mutant proteins, locking it in an inactive state
Brand names	Tabrecta	Krazati
Administrative route	Oral	Oral
Side effects	Peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite	Diarrhea, fatigue, nausea, vomiting, and decreased appetite
Contraindications	None known	None known
Drug class	Kinase inhibitor	KRAS G12C inhibitor
Manufacturer	Novartis Pharmaceuticals Corporation	Mirati Therapeutics, Inc.

Efficacy

Overview of Tabrecta (capmatinib) for Lung Cancer

Tabrecta (capmatinib) is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic). It is specifically indicated for patients whose tumors have a mutation that leads to MET exon 14 skipping, as detected by an FDA-approved test. The efficacy of Tabrecta was demonstrated in a clinical trial where patients with this specific genetic alteration showed a significant response to the treatment. The response rate and duration of response were key measures indicating the effectiveness of Tabrecta in shrinking tumors and slowing disease progression in this patient population.

Efficacy Results from Clinical Trials of Tabrecta

In the clinical trials, Tabrecta showed a notable objective response rate (ORR), with many patients experiencing a reduction in tumor size. This response was observed across different patient subgroups, including those previously treated with chemotherapy and/or immunotherapy. The duration of response (DoR) varied among patients, with some maintaining their response for an extended period. These results underscore Tabrecta's potential as an effective treatment option for patients with MET exon 14 skipping NSCLC, particularly for those who have limited treatment options due to the specific genetic makeup of their cancer.

Overview of Krazati (adagrasib) for Lung Cancer

Krazati (adagrasib) is another targeted therapy that has shown promise in the treatment of lung cancer. While it has not yet received FDA approval at the time of this writing, it has been under investigation for its efficacy in patients with NSCLC harboring the KRAS G12C mutation. This mutation is present in a subset of NSCLC cases and has historically been difficult to target with existing therapies. Early clinical trial data for adagrasib has indicated a favorable response rate in patients with the KRAS G12C mutation, suggesting that it could offer a new avenue of hope for individuals with this challenging genetic profile.

Efficacy Results from Clinical Trials of Krazati

The clinical trials evaluating Krazati (adagrasib) have focused on its ability to inhibit the mutated KRAS protein, thereby impeding cancer cell growth and proliferation. Preliminary results have shown a significant ORR in patients with the KRAS G12C mutation who were treated with adagrasib. The DoR and progression-free survival (PFS) data from these trials have also been encouraging, indicating that adagrasib could potentially provide a durable response for patients. As research continues, the full scope of Krazati's efficacy and its place in the treatment landscape for NSCLC will become clearer, especially for those with the KRAS G12C mutation.

Regulatory Agency Approvals

Tabrecta

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Krazati

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Tabrecta or Krazati today

If Tabrecta or Krazati are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Tabrecta

Buy Krazati

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: